Autopsy report · NCT00193024
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Cause of deathNo reason given
Life of this trial
- Registered 4 years after it had already started.
- Ran for about 3 years 1 month before it stopped.
- 90 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- SCRI Development Innovations, LLC
- Sponsor type
- University, hospital or other
- Conditions
- Breast Cancer
- Interventions
- Docetaxel; Epirubicin
- Participants
- 90
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.